XML 44 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurements And Financial Instruments (Tables)
9 Months Ended
Sep. 27, 2014
Fair Value Disclosures [Abstract]  
Summary Of Components Of Available-For-Sale Securities
The following table summarizes the components of the balance of the Company’s available-for-sale securities at September 27, 2014 and December 28, 2013 (in millions):
 
September 27, 2014
 
December 28, 2013
Adjusted cost
$
6

 
$
7

Gross unrealized gains
23

 
28

Fair value
$
29

 
$
35

Summary Of Financial Assets Measured At Fair Value On A Recurring Basis
A summary of financial assets measured at fair value on a recurring basis at September 27, 2014 and December 28, 2013 is as follows (in millions):
 
Balance Sheet
Classification
September 27, 2014
 
Quoted Prices
In Active
Markets
(Level 1)
 
Significant
Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets
 
 

 
 

 
 

 
 

Money-market securities
Cash and cash equivalents
$
667

 
$
667

 
$

 
$

Available-for-sale securities
Other current assets
29

 
29

 

 

Trading securities
Other assets
298

 
298

 

 

Total assets
 
994

 
994

 

 

 
 
 
 
 
 
 
 
 
Liabilities
 
 
 
 
 
 
 
 
Contingent consideration
Other current liabilities
148

 

 

 
148

Contingent consideration
Other liabilities
58

 

 

 
58

Total liabilities
 
$
206

 
$

 
$

 
$
206


 
Balance Sheet
Classification
December 28, 2013
 
Quoted Prices
In Active
Markets
(Level 1)
 
Significant
Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets
 
 

 
 

 
 

 
 

Money-market securities
Cash and cash equivalents
$
875

 
$
875

 
$

 
$

Available-for-sale securities
Other current assets
35

 
35

 

 

Trading securities
Other assets
279

 
279

 

 

Total assets
 
1,189

 
1,189

 

 

 
 
 
 
 
 
 
 
 
Liabilities
 
 
 
 
 
 
 
 
Contingent consideration
Other liabilities
195

 

 

 
195

Total liabilities
 
$
195

 
$

 
$

 
$
195

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]
The recurring Level 3 fair value measurements of the Company's contingent consideration liability include the following significant unobservable inputs (in millions):
Contingent Consideration Liability
Fair Value as of September 27, 2014
Valuation Technique
 
Unobservable Input
 
Range
 
 
 
 
 
 
 
 
 
Endosense regulatory-based milestone
$
148

Probability Weighted Discounted Cash Flow
 
Discount Rate
 
1.05%
-
1.51%
 
 
 
 
Probability of Payment
 
 
 
95%
 
 
 
 
Projected Year of Payment
 
 
 
2014
 
 
 
 
 
 
 
 
 
Nanostim revenue-based milestone
58

Probability Weighted Discounted Cash Flow
 
Discount Rate
 
 
 
5.00%
 
 
 
 
Probability of Payment
 
 
 
100%
 
 
 
 
Projected Years of Three Annual Payments
 
2016, 2017, 2018
Total contingent consideration liability
$
206

 
 
 
 
 
 
 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table provides a reconciliation of the beginning and ending balances of the Company' contingent consideration liability associated with its Endosense and Nanostim acquisitions since December 28, 2013 as of September 27, 2014 (in millions):
 
Endosense
Nanostim
Total
Balance as of December 28, 2013
$
139

$
56

$
195

Change in fair value of contingent consideration

1

1

Foreign currency translation
2


2

Balance as of March 29, 2014
141

57

198

Change in fair value of contingent consideration
7

1

8

Foreign currency translation



Balance as of June 28, 2014
148

58

206

Change in fair value of contingent consideration
8


8

Foreign currency translation
(8
)

(8
)
Balance as of September 27, 2014
$
148

$
58

$
206